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Long non-coding RNAs (lncRNAs) transcribed from intergenic and intronic regions of the
human genome constitute a broad class of cellular transcripts that are under intensive
investigation.WhileonlyahandfuloflncRNAshavebeencharacterized,theirinvolvementin
fundamental cellular processes that control gene expression highlights a central role in cell
homeostasis.Notsurprisingly,aberrantexpressionofregulatorylncRNAshasbeenincreas-
ingly documented in different types of cancer, where they can mediate both oncogenic or
tumor suppressor effects. Interaction with chromatin remodeling complexes that promote
silencing of speciﬁc genes or modulation of splicing factor proteins seem to be two general
modes of lncRNA regulation, but it is conceivable that additional mechanisms of action are
yet to be unveiled. LncRNAs show greater tissue speciﬁcity compared to protein-coding
mRNAs making them attractive in the search of novel diagnostics/prognostics cancer bio-
markers in body ﬂuid samples. In fact, lncRNA prostate cancer antigen 3 can be detected
in urine samples and has been shown to improve diagnosis of prostate cancer.We suggest
that an unbiased screening of the presence of RNAs in easily accessible body ﬂuids such
as serum and urine might reveal novel circulating lncRNAs as potential biomarkers in many
types of cancer. Annotation and functional characterization of the lncRNA complement
of the cancer transcriptome will conceivably provide new venues for early diagnosis and
treatment of the disease.
Keywords: long non-coding RNA, cancer, diagnostics, expression signature
Over the last decade, advances in genome-wide analyses of the
eukaryotic transcriptome have revealed that most of the human
genome is transcribed, generating a large repertoire of (>200nt)
long non-coding RNAs (lncRNAs) that map to intronic and inter-
genic regions (Birney et al., 2007; Dinger et al., 2009; Ponting
et al., 2009; Kapranov et al., 2010). These include subsets of
polyadenylated and non-polyadenylated transcripts that accumu-
late differently in the nucleus and cytoplasm of cells (Kapranov
et al., 2007, 2010). The catalog of human lncRNAs has expanded
dramatically just in the last several years; in fact, recently pub-
lished deep RNA sequencing reveals that the range, depth, and
complexity of the human transcriptome is far from fully charac-
terized (Mercer et al., 2012) and expectations are that very soon
the human lncRNA genes will outnumber protein-coding genes.
The deﬁnition and naming of lncRNAs are currently evolving
in the literature and different classes or categories of lncRNA
have been described (Prensner and Chinnaiyan, 2011; Wright
and Bruford, 2011). The categorization recently proposed by the
HUGO Gene Nomenclature Committee (HGNC) is an ongo-
ing project (Wright and Bruford, 2011), where lncRNAs were
described as spliced, capped, and polyadenylated RNAs (Wright
and Bruford, 2011); this clearly does not encompass all different
lncRNAs that may be also unspliced and/or non-polyadenylated
(Nakaya et al., 2007; Kapranov et al., 2010; Yang et al., 2011a).
The rapid increase in the number of described lncRNAs along
withthelackof uniformandsystematicannotationnomenclature
for the diverse and extensive amount of lncRNAs expressed in
human tissues imposes a considerable limitation regarding the
completeness of any database related to lncRNAs (Paschoal et al.,
2012).
It is apparent that lncRNAs may act through diverse molecular
mechanismsandplayregulatoryandstructuralrolesinimportant
biological processes (see Mattick, 2009 for a review). Presently,
the mechanisms of action of only a few lncRNAs have been char-
acterized in detail (Wang and Chang, 2011), and many of these
lncRNAs have an altered expression in different types of human
cancer (Huarte and Rinn, 2010; Gibb et al., 2011; Prensner and
Chinnaiyan, 2011).
Cancers are the result of a process where somatic cells mutate
and escape the controlled balance exerted by gene expression pro-
grams and cellular networks that maintain cellular homeostasis
and normally prevent their unwanted expansion. Cancer cells
differfromnormalcellsinmanyimportantcharacteristics,includ-
ing loss of differentiation, increased invasiveness, and decreased
drug sensitivity. Genes that affect these processes can be classiﬁed
into two major groups: tumor suppressor genes and oncogenes.
Tumor suppressor genes protect cells against mutations that ini-
tiate transformation. Conversely, oncogenes initiate the cellular
transformation process when inappropriately activated. LncRNAs
have been recently implicated as having tumor suppressor and
oncogenicroles(HuarteandRinn,2010;Gibbetal.,2011;Prensner
and Chinnaiyan, 2011).
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GENERAL MECHANISMS OF lncRNA FUNCTION IMPLICATED
IN CANCER
Long non-coding RNAs can activate cellular pathways that lead
to tumorigenesis, in analogy to protein-coding oncogenes. The
molecular mechanisms by which lncRNAs exert their biological
functions has been extensively reviewed by (Wang and Chang,
2011). Here we highlight some examples of lncRNAs implicated
in oncogenic functions.
One example of such an oncogenic lncRNA is metastasis-
associated in lung adenocarcinoma transcript 1 (MALAT1), a
nuclear-retained non-coding RNA that has been recently shown
toregulatealternativesplicingbymodulatingserine/arginine(SR)
splicing factor phosphorylation (Tripathi et al., 2010). Increased
expression of the lncRNA MALAT1 has been ﬁrst observed in
metastatic non-small cell lung cancer (Ji et al., 2003; see details in
the next section),followed by endometrial stromal sarcoma of the
uterus (Yamada et al., 2006), and more recently in six other types
of cancer, including hepatocellular carcinoma, breast, pancreas,
lung,colon,and prostate cancers (Lin et al.,2007). Recently,short
hairpinRNAinhibitionofMALAT1inhumancervicalcancercells
was shown to suppress cell proliferation and invasion (Guo et al.,
2010), whereas RNA interference-mediated silencing of MALAT1
reduced the in vitro migration of lung adenocarcinoma cells by
inﬂuencing the expression of motility-related genes (Tano et al.,
2010). Altogether, these ﬁndings reinforce the role of MALAT1 as
an oncogenic lncRNA, and point to one of the possible modes
of action of lncRNAs, namely through their interaction with and
modulation of splicing factor proteins.
The mode of action of lncRNAs through the interaction with
chromatin remodeling complexes may be a more general one, as
it has been documented for two lncRNAs. One example is ANRIL
(antisensenon-codingRNAintheINK4locus)thatisalteredinan
estimated 30–40% of human tumors (Kim and Sharpless, 2006).
Tumor suppressor p15INK4B is silenced by its antisense ANRIL
transcript (Yu et al., 2008); lncRNA ANRIL is required for the
recruitmentofpolycombPRC1andPRC2complexestotheINK4B
locus and for silencing of p15INK4B tumor suppressor gene (Yap
et al.,2010; Kotake et al., 2011).
AnotherexampleisHOTAIR(HOXAntisenseIntergenicRNA),
a metastasis-associated gene located in the mammalian HOXC
locusthatreprogramschromatinstatetopromotecancermetasta-
sis(Guptaetal.,2010).HOTAIRlncRNAinteractswithPolycomb
Repressor Complex PRC2, determining PRC2 localization and
repression of the HOXD locus (Rinn et al., 2007). Recently it was
foundthatHOTAIRservesasascaffoldforatleasttwodistincthis-
tone modiﬁcation complexes. HOTAIR binds the PRC2 complex
responsibleforH3K27methylationandalsoLSD1,ahistonelysine
demethylasethatmediatesenzymaticdemethylationof H3K4Me2
(Tsai et al., 2010). Although the precise mechanism of HOTAIR
activities remains to be elucidated,it is clear that HOTAIR partic-
ipates in silencing of metastasis suppressor genes thus promoting
metastasis,as discussed below.
LARGE-SCALE EXPRESSION PROFILING OF lncRNAs IN
PATIENTS
Cancer gene proﬁling studies have had an enormous impact on
understandingof thebiologyof cancers,pointingtothebiological
heterogeneity of speciﬁc cancer types, providing identiﬁcation
of novel oncogenes and tumor suppressors, and deﬁning path-
ways that interact to drive the growth of individual cancers
(Cowin et al., 2010). Large-scale genomic studies are under-
way, such as The Cancer Genome Atlas project that aims to
catalog in each cancer type the changes in DNA copy num-
ber and methylation, as well as in small (19–25nt) non-coding
microRNA(miRNA)andprotein-codingmRNAexpression(Can-
cer_Genome_Atlas_Research_Network,2008,2011). Noteworthy,
changes in expression of lncRNAs have not been analyzed in these
large cohort studies.
Identiﬁcation of lncRNAs correlated to cancer has beneﬁted
in the past decade from the development of a number of effec-
tive high-throughput expression analyses technologies as well as
from the increasing realization that lncRNAs may play important
roles in physiological and pathological processes in the cell (see
Table 1). Early efforts to identify molecular cancer markers based
on the screening of cDNA libraries enriched in tumor-speciﬁc
transcripts have identiﬁed lncRNAs whose expression levels cor-
relate to cancer. Using a differential display approach,the lncRNA
DD3, later named prostate cancer antigen 3 (PCA3), was initially
identiﬁed as overexpressed in prostate tumors relative to benign
prostate hyperplasia and normal epithelium (Bussemakers et al.,
1999). Further studies later indicated that PCA3 is a very spe-
ciﬁc prostate cancer gene whose mechanism of action is still not
identiﬁed (Marks and Bostwick, 2008; Shappell,2008).
Another report that used large-scale transcriptome analysis to
look for differential gene expression in cancer and gave attention
to a differentially expressed lncRNA, namely MALAT1, employed
a subtractive hybridization approach to determine differences
in gene expression between primary non-small cell lung cancer
tumors of ﬁve patients that were cured by surgery and tumors of
fourpatientsthatsubsequentlymetastasized(Jietal.,2003).Inall,
26 transcripts were found more than once, and among them the
novel lncRNA named MALAT1. Subsequently, 31 samples from
stage I patients suffering from adenocarcinoma or squamous cell
carcinoma were analyzed by qPCR, and the expression levels of
MALAT1weresigniﬁcantlyhigherinmetastasizingadenocarcino-
mascomparedtonon-metastasizingones(p =0.03);interestingly,
no signiﬁcant differences in gene expression were found for squa-
mous cell carcinomas (n =34;Ji et al.,2003). These data provided
evidence that the association of lncRNA MALAT1 with metastasis
depended on the lung tumor’s histology.
A large-scale gene expression approach speciﬁcally designed to
lookforlncRNAscorrelatedtocancerhasemployedhybridization
of RNA derived from normal human breast epithelia, primary
breast carcinomas, and distant metastases to ultra-dense tiling
arrays covering the entire HOX gene loci (Gupta et al., 2010).
The authors found that 233 transcribed regions in the HOX loci,
comprising 170 lncRNAs and 63 HOX exons, were differentially
expressed (Gupta et al., 2010), with a systematic variation in
the expression of HOX lncRNAs among normal breast epithe-
lia, primary tumor, and metastases. Dozens of HOX lncRNAs
were expressed in normal breast but showed reduced expression
in all cancer samples; conversely, a set of HOX lncRNAs was fre-
quentlyexpressedinprimarytumorsbutnotinmetastases(Gupta
et al., 2010). Notably, one such metastasis-associated lncRNA was
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HOTAIR, which had a unique association with patient prognosis
(Gupta et al.,2010).
Oligoarrays were used to interrogate 481 ultra conserved
regions (UCRs) in the human genome (Calin et al., 2007); UCRs
are a subset of conserved sequences that are located in both
intra-andintergenicregionsandareabsolutelyconserved(100%)
between orthologous regions of the human, rat, and mouse
genomes (Bejerano et al., 2004). A total of 256 UCRs (53%) were
identiﬁed as non-coding genomic regions (Bejerano et al., 2004).
The authors investigated the expression of UCRs in a panel of 173
samples, including 133 human cancers [e.g., chronic lymphocytic
leukemias (CLL), colorectal (CRC), and hepatocellular carcino-
mas (HCC)] and 40 corresponding normal tissues (Calin et al.,
2007). Speciﬁc sets of UCRs were differentially expressed in dis-
tinct tumor types, and among them, 42 were non-coding UCRs
(48% of the differentially expressed UCRs). This work demon-
strated that the transcribed UCR expression proﬁles can be used
to differentiate human cancers (Calin et al.,2007).
Custom-designed cDNA microarrays interrogating selected
setsofprotein-codinggenesandlncRNAsfromintronic/intergenic
genomic regions were used for obtaining expression proﬁles from
clinicalsamplesofanumberofcancertypes(Reisetal.,2004;Brito
et al., 2008; Tahira et al., 2011). In prostate cancer, RNA from 27




score), 23 were lncRNAs mapping to intronic regions (Reis et al.,
2004). Among the top twelve transcripts most signiﬁcantly corre-
latedtotumordifferentiation,sixwereantisenseintroniclncRNAs
asshownbyorientation-speciﬁcRT-PCRornorthernblotanalysis
with strand-speciﬁc riboprobe (Reis et al.,2004).
Aberrant expression of intronic lncRNAs was studied in clear
cell renal cell carcinoma (RCC) using matched samples of tumor
and adjacent non-neoplastic tissue obtained from six patients
(Brito et al., 2008). A set of 55 transcripts was signiﬁcantly
down-regulated in clear cell RCC relative to the matched non-
tumor tissue; among the down-regulated transcripts, 49 mapped
to untranslated or coding exons of protein-coding genes and 6
were lncRNAs mapped to intronic regions in genomic loci of
protein-coding genes (Brito et al., 2008).
More recently, pancreatic ductal adenocarcinoma (PDAC) was
studied, aiming at identifying gene expression proﬁles of protein-
codingandlncRNAscorrelatedtopancreaticcancerandmetastasis
in 38 clinical samples of tumor and non-tumor pancreatic tissues
(Tahira et al., 2011). Statistically signiﬁcant expression signatures
comprising protein-coding mRNAs and intronic/intergenic lncR-
NAs that correlate to PDAC or to pancreatic cancer metastasis
wereidentiﬁed;interestingly,lociharboringintroniclncRNAsdif-
ferentially expressed in PDAC metastases were enriched in genes
associated to the MAPK pathway (Tahira et al., 2011).
Whole-genometilingarrayswereutilizedtoidentifytheexpres-
sion of novel lncRNAs across the entire human genome (Perez
et al., 2008). The authors hybridized RNA from normal lung cell
cultures to the tiling arrays and found 495 transcriptionally active
regions originated from non-protein-coding sequence (intergenic
or intronic regions) and chose 15 candidate RNAs for subsequent
real-time RT–PCR,northern blot,and sequencing experiments of
which three were intronic lncRNAs (Perez et al., 2008). Altered
expression of these lncRNAs was found in patient samples in both
breast and ovarian cancers (Perez et al., 2008).
The ﬁrst high-throughput sequencing of polyA+ RNA (RNA-
seq) from a large cohort of 102 prostate tissues and cells lines
has been recently reported (Prensner et al., 2011). The work has
identiﬁed 121 unannotated prostate cancer-associated lncRNA
transcripts (PCATs) and has characterized one lncRNA, PCAT-1,
asaprostate-speciﬁcregulatorof cellproliferation,showingthatit
is a target of PRC2 (Prensner et al.,2011). Patterns of PCAT-1 and
PRC2 expression stratiﬁed patient tissues into molecular subtypes
distinguishedbyexpressionsignaturesof PCAT-1-repressedtarget
genes. These ﬁndings establish the utility of RNA-seq to identify
disease-associated lncRNAs that may improve the stratiﬁcation of
cancer subtypes (Prensner et al., 2011).
Although the functional consequences of the deregulation of
lncRNAs in cancer development are currently unknown,the stud-
ies discussed above indicate that this class of transcripts may play
important functions in both normal and malignant tissues.
lncRNAs AS A DIAGNOSTIC TEST TOOL
Molecular markers of malignancy are important diagnostic and
prognostic tools that help patient management in the oncology
clinics. Cancer is a multi-factorial disease and for most types of
malignancies an increase in the number of available assessment
and management tools is desirable. Expression of the lncRNA
MALAT1 has been identiﬁed by Kaplan–Meier analyses as a prog-
nostic parameter for patient survival in stage I non-small cell lung
cancer(Jietal.,2003).MALAT1hasbeensubsequentlyvalidatedas
a marker for endometrial stromal sarcoma of the uterus (Yamada
et al., 2006) and for HCC and a spectrum of ﬁve other human
carcinomas (Lin et al., 2007). In addition, increased expression
of MALAT1 has been recently shown to be an independent prog-
nostic factor for HCC following liver transplantation (Lai et al.,
2011).
IncreasedexpressionoflncRNAHOTAIRwasshowntobeasso-
ciated with metastasis in breast cancer patients, having a unique
association with patient prognosis (Gupta et al., 2010). Subse-
quently, HOTAIR expression levels was found to correlate with
metastasis in colorectal carcinoma (Kogo et al.,2011),and to pre-
dict tumor recurrence in hepatocellular carcinoma (Yang et al.,
2011b).
At present, few lncRNAs have been characterized as potential
biomarkers in human ﬂuids. Measurement of lncRNA PCA3 in
patient urine samples has been shown to allow more sensitive and
speciﬁc diagnosis of prostate cancer than the widely used PSA
(prostate-speciﬁc antigen) serum levels (Fradet et al., 2004; Tinzl
et al., 2004; Shappell, 2008). The potential of PCA3 urine assay
to aid prostate cancer diagnosis and minimize unnecessary biop-
sies has been extensively documented, highlighting its advantages
overPSAandpointingtofuturechallengesforthisnewdiagnostic
biomarker (Lee et al., 2011).
The lncRNA HULC (highly upregulated in liver cancer) is
highly expressed in HCC patients and can be detected in the
blood by conventional PCR methods (Panzitt et al., 2007). It has
been later shown that HULC lncRNA expression is not conﬁned
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to HCC, but is also expressed in colorectal carcinomas that
metastasize to the liver (Matouk et al.,2009).
Diagnosis and treatment follow up of complex multi-factorial
diseases such as cancer could conceivably be improved by screen-
ingof alargernumberof molecularbiomarkersineasilyaccessible
samplespecimens.Infact,highlystablecell-freecirculatingnucleic
acids (cfCNA), both RNA and DNA species, have been discov-
ered in the blood, plasma, and urine of humans (Tong and Lo,
2006). At present, there is evidence of a good correlation between
tumor-associated changes in genomic, epigenetic, or transcrip-
tional patterns and alterations in cfCNA levels (Schwarzenbach
etal.,2011),stronglypointingtotheutilityofthisbloodbiomarker
class as promising clinical tools.
The release of nucleic acids into the blood is thought to be
related to the apoptosis and necrosis of cancer cells in the tumor
microenvironment and is also the result of secretion. Circulating
RNAs are detectable in the serum and plasma of cancer patients,
being surprisingly stable in spite of the fact that high amounts of
RNases circulate in the blood of cancer patients. This implies that
RNA may be protected from degradation by its packaging into
microparticles, which include exosomes, microvesicles, apoptotic
bodies, and apoptotic microparticles (Orozco and Lewis, 2010).
Microparticles are small, membranous vesicles that can contain
DNA, RNA, miRNA, intracellular proteins, and extracellular sur-
face markers from the parental cells; they can be secreted from
intracellular multivesicular bodies or released from the surface
of blebbing membranes (Cocucci et al., 2009; Orozco and Lewis,
2010). The detection and identiﬁcation of RNA in serum and
plasmacanbecarriedoutusingmicroarraytechnologiesorreverse




Recent advances in small non-coding miRNA expression pro-
ﬁling in human cancer and their potential as therapeutic targets
and novel biomarkers have been reviewed (Farazi et al., 2011;
Munker and Calin, 2011). The presence of small non-coding
miRNAs in serum of cancer patients was ﬁrst described for dif-
fuse large B-cell lymphoma patients (Lawrie et al., 2008). Cir-
culating miRNAs were subsequently used in assessing patients
with prostate cancer (Mitchell et al., 2008) and at present cir-
culating miRNAs have been characterized as potential biomark-
ers in over ten different cancers (Kosaka et al., 2010). Despite
being promising biomarkers for cancer diagnosis and prog-
nosis, there have been conﬂicting ﬁndings about circulating
miRNAs from the same tumor reported from different stud-
ies (Kosaka et al., 2010). These discrepancies might be due
to the lack of an established endogenous miRNA control to
normalize for circulating miRNA levels, and also to the dif-
ferent extraction and quantiﬁcation methods used among the
studies (Kosaka et al., 2010). An effort to standardize results is
warranted by putting forward recommendations for controlling
pre-analytical variables, including the reduction of contaminant
cellular miRNAs of hematopoietic origin in the isolation and
quantization of cell-free circulating RNAs (Duttagupta et al.,
2011).
We speculate that in addition to miRNAs and mRNAs the
human serum might contain a considerable amount of lncR-
NAs that will eventually be detected by the use of unbiased
high-throughput technologies such as genome tiling expression
microarraysorRNA-seqdeep-sequencingof serumsamples.Such
approaches should be subjected to the same controls regarding
pre-analytical variables (Duttagupta et al., 2011), including the
reduction of contaminant hematopoietic cells in the isolation and
quantization of cell-free circulating lncRNAs.
Comparative studies of lncRNAs in serum from cancer patient
large cohorts and from normal subjects will possibly reveal novel
circulating lncRNAs as potential biomarkers in many types of
cancers.
CONCLUSION AND PERSPECTIVES
Long non-coding RNA expression proﬁles in human cancers
have highlighted the potential value of this class of non-coding
RNAs as tumor markers in patient diagnosis and prognosis.
The rapidly expanding catalog of lncRNAs holds promises that
in the near future lncRNAs will become ever more important
in cancer patient management. An analogy can be made with
the impact of small miRNA proﬁling in many types of cancer
(Braconi et al., 2011; Ferracin et al., 2011; Schetter and Harris,
2011; Wang and Sen, 2011), which has provided different experi-
mental lines of evidence that deregulation of miRNAs not only
results as consequence of cancer progression but also directly
affects gene networks that promote tumor initiation and pro-
gression in a cause-effect manner (Lovat et al., 2011). As the
catalog of lncRNAs grows, it will become important to elucidate
the genetic networks and pathways regulated by the abnormally
expressing lncRNAs in cancer cells as a means to understand-
ing the role of these lncRNAs in the induction of malignant
transformation.
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